AEGLEA BIOTHERAPEUTICS, INC.
805 Las Cimas Parkway
Suite 100
Austin, TX 78746
June 4, 2021
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
| Attention: | Alan Campbell Office of Life Sciences | |
| Re: | Aeglea BioTherapeutics, Inc. Registration Statement on Form S-3 Filed May 28, 2021 File No. 333-256614 | |
Via EDGAR - Acceleration Request
| Requested Date: | June 8, 2021 | |
| Requested Time: | 4:00 p.m. Eastern Time | |
Ladies and Gentlemen:
Aeglea BioTherapeutics, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to make the above-captioned Registration Statement on Form S-3 effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable.
The Registrant hereby authorizes Robert A. Freedman or Ryan Mitteness, both of whom are attorneys with the Registrant’s outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration.
| Sincerely, | ||
| AEGLEA BIOTHERAPEUTICS, INC. | ||
| By: | /s/ Anthony Quinn | |
| Anthony Quinn | ||
| Chief Executive Officer | ||
| cc: | Robert A. Freedman, Esq. |
Ryan Mitteness, Esq.
Fenwick & West LLP